Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors

Purpose: Checkpoint inhibitors have significantly improved treatment of metastatic melanoma. However, 40–60% of patients do not respond to therapy, emphasizing the need for better predictive biomarkers for treatment response to immune checkpoint inhibitors. Prorammed death-ligand 1(PD-L1) expression...

Full description

Bibliographic Details
Main Authors: Jesper Geert Pedersen, Anne Tranberg Madsen, Kristine Raaby Gammelgaard, Ninna Aggerholm-Pedersen, Boe Sandahl Sørensen, Trine Heide Øllegaard, Martin Roelsgaard Jakobsen
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
melanoma
biomarkers
cytokines
inflammation
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/12/6/1414

Internet

https://www.mdpi.com/2072-6694/12/6/1414

Similar Items